

VIAGENEX™



➤ AMNIOTIC ALLOGRAFTS

IMMUNE PRIVILEGED anatomical barriers that provide mechanical PROTECTION for surgically traumatized tissue while retaining an array of preserved endogenous growth factors.

VIAGENEX™


VIAGENEX™ is a family of amniotic allografts processed to retain the inherent mechanical properties of amniotic tissue and rich supply of extracellular matrix, growth factors and cytokines.^{1,2}

▶ VIAGENEX AMNIOTIC ALLOGRAFT FEATURES AND BENEFITS

Amniotic-derived tissues may be used as a soft tissue barrier and wound covering that retains endogenous extracellular matrix (ECM), growth factors and cytokines²⁻⁵ essential for signaling. The properties of amniotic tissue help provide mechanical protection⁶ to damaged tissue while retaining nutrient-rich growth factors.⁷⁻⁹

WHY VIAGENEX MATRIX AMNION/CHORION ALLOGRAFT

- Amniotic tissue acts as a mechanical barrier between mother and fetus as well as an immune-privileged protective barrier during fetal development.¹
- VIAGENEX applied as a soft tissue and wound covering helps provide the same mechanical protection to support the damaged tissue.⁵
- VIVEX's Integrity Processing™ retains the intermediate (spongy) layer and **preserves** the inherent properties of amniotic tissues, maintaining key extracellular matrix molecules, proteins, carbohydrates, growth factors and cytokines.⁷
- VIAGENEX Matrix:
 - 5-year shelf life for room temperature storage
 - No upfront preparation – hydrates in site
 - 4X thicker than single layer amniotic allografts



WHY VIAGENEX MAX UMBILICAL CORD MEMBRANE ALLOGRAFT

- Thickest amniotic membrane allograft, 800-1,000µm (1mm)
- Retains inherent extracellular matrix components, growth factors and cytokines
- Robust enough to be sutured in place
- Excellent handling properties
- VIAGENEX Max:
 - 5-year shelf life for room temperature storage
 - No upfront preparation – hydrates in site
 - 2X thicker than amnion/chorion amniotic allografts



► **KNOWN GROWTH FACTORS AND EXTRACELLULAR MATRIX (ECM) PROTEINS IN AMNIOTIC ALLOGRAFTS AND THEIR CORRESPONDING ROLE** ^{28,29}


GROWTH FACTORS	ROLE	ECM PROTEINS	ROLE
MCP-1 ²⁵ , IL1-RA ²¹ , TGF-β1&2 ¹⁶ , IL6 ²¹	Immune Modulation / Anti-Inflammatory	Collagen, type I-VII	Main structural protein component in the body
TNF-α ²⁶ , GRO-α ²⁴ , HGF ¹² , IGF1&2 ^{13,15} , VEGF ¹⁷ , βFGF ¹⁸ , PDGFα&β ²⁰ , Ang ²²	Angiogenesis	Fibronectin	Binding protein agent, supports initial cell attachment
EGF ¹⁹ , FGF ¹⁸ , TGFβ ¹⁶ , TIMP(1-4) ¹⁰ , HGF ¹¹	Cell Growth	Hyaluronic Acid	Lubricating hydrophilic protein that coats cells and aids in hydrodynamic movements
PDGFα&β ²⁰ , EGF ¹⁹ , TIMP-2&-3 ¹⁰ , HGF ¹¹ , Ang ²² , KGF ²³	Cell Migration	Laminin	High molecular weight protein to which cells easily bind and migrate across
PDGFα&β ²⁰ , EGF ¹⁹ , FGF ¹⁸ , TGF-β1&2 ¹⁶ , IGF1&2 ¹⁴ , Ang ²² , KGF ²³	Cell Proliferation	Proteoglycans	Connective proteins that fill the spaces between cells in tissue and affect the stability of the proteins and growth factors
PDGFα&β ²⁰ , EGF ¹⁹ , TIMP-2&-3 ¹⁰ , TGF-β1&2 ¹⁶	Cell Differentiation		

THE PROPRIETARY INTEGRITY PROCESSING™ PRESERVES UP TO 600+ SIGNALING PROTEINS IN VIAGENEX MATRIX AND MAX³⁰


► **POTENTIAL CLINICAL APPLICATIONS**

In general orthopedics, arthroplasty, hand and wrist, and foot and ankle procedures, VIAGENEX has been used as a protective barrier to provide essential mechanical protection^{6,27} for surgically traumatized tissues. Other potential clinical applications for VIAGENEX include:


- Spine & Neurosurgery
- Wound Care
- Burn Care
- Oral Surgery
- Shoulder
- Nerves
- Knees
- Tendons
- OB/GYN
- Urology




SPINE



NERVE WRAP



WOUND



ANKLE

▶ SAFE AND TRUSTED PARTNER

VIVEX Biologics is a regenerative solutions company, focusing on patient care through the innovation of tissue and biologic-based therapies in Wound Care, Ortho-Fusion and Interventional Pain. With more than 50 years of highly safe and effective operations, VIVEX aims to provide advanced regenerative solutions.

- Amniotic tissue is recovered from healthy mothers at live births.
- Handled and processed in accordance with both FDA regulations and AATB standards.
- VIVEX has distributed over 1 million allografts since 2010.
- No reported adverse events and no reported disease transmission.

▶ ORDERING INFORMATION

CATALOG NUMBER	DESCRIPTION	SIZE
VIA GENEX MATRIX	AMNION/CHORION ALLOGRAFT	
VGM020600S	VIAGENEX™ Matrix Amnion Allograft	2x6cm
VGM040400S	VIAGENEX™ Matrix Amnion Allograft	4x4cm
VGM040600S	VIAGENEX™ Matrix Amnion Allograft	4x6cm
VGM040800S	VIAGENEX™ Matrix Amnion Allograft	4x8cm
VGM021200S	VIAGENEX™ Matrix Amnion Allograft	2x12cm
VGM070600S	VIAGENEX™ Matrix Amnion Allograft	7x6cm
VIA GENEX MAX	UMBILICAL CORD MEMBRANE ALLOGRAFT	
VGC020300S	VIAGENEX™ Max Umbilical Cord Membrane	2x3cm
VGC030300S	VIAGENEX™ Max Umbilical Cord Membrane	3x3cm
VGC030400S	VIAGENEX™ Max Umbilical Cord Membrane	3x4cm
VGC030500S	VIAGENEX™ Max Umbilical Cord Membrane	3x5cm
VGC030600S	VIAGENEX™ Max Umbilical Cord Membrane	3x6cm
VGC030800S	VIAGENEX™ Max Umbilical Cord Membrane	3x8cm

CORRECT



Epithelial side up

INCORRECT



Product HCPCS Code: Q4100, per sq cm

- Rowlatt, U. (1979), Intrauterine wound healing in a 20-week human fetus. *Virchows Arch A Pathol Anat Histol*, 381(3), 353-361
- Coelen, N.A. et al. (2010). Comparison between human fetal and adult skin. *Archives of Dermatological Research*, 302(1), 47-55.
- Coelen NA, Schouten KC, Boekema BK, Middelkoop E, Ulrich MM. Wound healing in a fetal, adult, and scar tissue model: a comparative study. *Wound Repair Regen*. 2010;18(3):291-301. doi:10.1111/j.1524-475X.2010.00585.x.
- Tseng SC, Espana EM, Kawakita T, et al. How does amniotic membrane work? *Ocul Surf*. 2004;2(3):177-187
- Riordan NH, George BA, Chandler TB, McKenna RW. Case report of non-healing surgical wound treated with dehydrated human amniotic membrane. *J Transl Med*. 2015;13:242. doi:10.1186/s12967-015-0608-8.
- Kim SS, Sohn SK, Lee KY, et al. Use of human amniotic membrane wrap in reducing perineural adhesions in a rabbit model of ulnar nerve neurotaphy. *J Hand Surg Eur Vol*. 2010;35(3):214-219. doi:10.1177/1753193409352410.
- Delcroix GJ, Namin S, D'Ippolito G, Temple HT, Marshall R. Preserving the natural regenerative potential of amniotic membrane. *Vivex Biomedical*.
- Niknejad H, Peirovi H, Jorjani M, et al. Properties of the amniotic membrane for potential use in tissue engineering. *Eur Cell Mater*. 2008;15:88-89.
- Koob TJ, Lim JJ, Massee M, Zabek N, Denoizier G. Properties of dehydrated human amnion/chorion composite grafts: implications for wound repair and soft tissue regeneration. *J Biomed Mater Res B Appl Biomater*. 2014;102(6):1353-1362. doi:10.1002/jbm.b.33141.
- Masciantonio M.G. et al., "Matrix Metalloproteinases and Tissue Remodeling in Health and Disease: Cardiovascular Remodeling" *Prog in Mol Bio & Trans Sci*, 2017
- Ynan Deng, et al. " Umbilical Cord-derived Mesenchymal Stem Cells Instruct Monocytes Towards an IL10-producing Phenotype by Secreting IL6 and HGF" *Scientific Reports* volume 6, Article number: 37566 (2016)
- G.V. Sherbet, "Growth Factors and Their Receptors in Cell Differentiation, Cancer and Cancer Therapy", 2011
- BENOIT ST-JACQUES, JILL A. HELMS, in *Pediatric Bone*, 2003
- R.W. Li, A.K. Sperling, in *Brenner's Encyclopedia of Genetics (Second Edition)*, 2001
- Alexander Brill, David Varon, in *Platelets (Second Edition)*, 2007
- Hans Link, Bao-Guo Xiao, "Transforming Growth Factor Beta" *Encyclopedia of Immunology 2nd edition*, 1998
- Angela M Duffy et al. "Vascular Endothelial Growth Factor (VEGF) and its Role in Non-Endothelial Cells: Autocrine Signaling by VEGF"
- Ye-Raan Yun et al. "Fibroblast Growth Factors: Biology, Function, and Application for Tissue Regeneration" *J Tissue Eng*, 2010;2010:218142
- Bodnar, Richard J. "Epidermal Growth Factor and Epidermal Growth Factor Receptor: The Yin and Yang in the Treatment of Cutaneous Wounds and Cancer"
- Giannoula Lakka Klement, David Varon et al. "The Role of Platelets in Angiogenesis"; *Platelets*, 3rd Edition 2013
- Lakshmi Srinivasan, Laurie E. Kilpatrick et al. "Cytokines and Inflammatory Response in the Fetus and Neonate"; *Fetal and Neonatal Physiology*, 5th edition, 2017
- Gao X, Xu Z (2008). "Mechanisms of action of angiogenin". *Acta Biochimica et Biophysica Sinica*. 40 (7): 619-624
- Jeffrey S. Rubin et al., "Keratinocyte Growth Factor", *Cell Biology International*, Vol 19, Issues 5, May 1995; p399-412
- Bechara, Carlos et al. "Growth related oncogene-alpha (GRO-alpha): roles in atherosclerosis, angiogenesis, and other inflammatory conditions"; *Med Sci Monit*, 2007 Jun;13(6):RA87-90
- Deshmune, Satish L. et al., "Review of Monocyte Chemoattractant Protein-1 (MCP-1)"; *Journal of Interferon & Cytokine Research*, Vol 29, #6, 2009
- Narayanan Parameswaran & Sonika Patel, "Tumor Necrosis Factor-alpha Signaling in Macrophages", *Crit Rev Eukaryot Gene Expr*. 2010 ; 20(2): 87-103
- Jarabek SA, Carroll KM, Michaels B, Mayman DJ. A pilot study to evaluate the safety and efficacy of amniotic membrane transplantation in patients with arthrofibrosis following total knee arthroplasty. *Hospital for Special Surgery*. http://www.annalsmedical.com/wp-content/uploads/Amniotic_Hip_Knee_Study.pdf. Accessed November 21, 2017
- Gerhard Meisenberg; William H. Simmons, "Principals of Medical Biochemistry"; Elsevier Health Sciences, pp. 243- ISBN 978-0-323-02942-1. February 2011.
- Yanagishita M et al., "Function of proteoglycans in the extracellular matrix" *Acta Pathol Jpn*, 1993 Jun;43(6):283-93
- Data on file at VIVEX Biologics, Inc.

VIVEX Biologics will use reasonable efforts to provide accurate and complete information herein, but this information should not be construed as providing clinical advice, dictating reimbursement policy or as a substitute for the judgment of a health care provider. It is the health care provider's responsibility to determine the appropriate treatment, codes, charges for services and use of modifiers for services rendered and to submit coverage or reimbursement-related documentation.